Senti BiosciencesSNTI
13F holders, Q2 2025 (June 30)14holders −1
1new positions
2sold out
$2.11avg. 13F price*
At the end of Q2 2025, 14 institutions reported holding Senti Biosciences Inc. (SNTI) in their 13F filings, down 1 from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were NEA Management Company, LLC ($8.0M), Armistice Capital, LLC ($1.9M) and Nantahala Capital Management, LLC ($1.9M).
- Company
- Senti Biosciences Inc.
- CUSIP
- 81726A209
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1.9M |
| Exits | 2 | $22K |
All 13F filers, Q1 2025 → Q2 2025: 1,235,620 shares bought and 414,401 shares sold, net +821,219 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| NEA Management Company, LLC | 0.60% | No change | 3,775,615 | $8.0M |
| Armistice Capital, LLC | 0.07% | New | 892,207 | $1.9M |
| Nantahala Capital Management, LLC | 0.13% | No change | 888,000 | $1.9M |
| Heights Capital Management, Inc. | 0.26% | Reduce -49.1% | 381,384 | $805K |
| Vanguard Group Inc. | 0.00% | Add +134.2% | 360,911 | $762K |
| Geode Capital Management, LLC | 0.00% | Add +395.6% | 147,314 | $311K |
| BlackRock, Inc. | 0.00% | Add +451.6% | 22,084 | $47K |
| State Street Corp. | 0.00% | No change | 10,010 | $21K |
| UBS Group AG | 0.00% | Reduce -89.8% | 4,412 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -21.3% | 1,121 | $2K |
| Barclays PLC | 0.00% | Add +1796.7% | 569 | $1K |
| Bank of America Corp. | 0.00% | Add +342.1% | 557 | $1K |
| SBI Securities Co., Ltd. | 0.00% | No change | 338 | $713 |
| Morgan Stanley | 0.00% | No change | 160 | $338 |
"% of holder's portfolio" is SNTI's weight in each manager's 13F, not the share of Senti Biosciences Inc. the manager owns.